NR3C2 and chronic kidney disease: Blockade of the aldosterone-binding mineralocorticoid receptor (MR) have consistently been shown to reduce blood pressure in hypertensive patients [6, 7] and slow the decline in kidney function observed in individuals suffering from CKD [8, 9].